Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for iBio (IBIO) over the last 12 years, with Q3 2025 value amounting to $53000.0.

  • iBio's Gains from Investment Securities fell 2638.89% to $53000.0 in Q3 2025 from the same period last year, while for Dec 2025 it was $206000.0, marking a year-over-year decrease of 2771.93%. This contributed to the annual value of $299000.0 for FY2025, which is 992.65% up from last year.
  • As of Q3 2025, iBio's Gains from Investment Securities stood at $53000.0, which was down 2638.89% from $78000.0 recorded in Q2 2025.
  • Over the past 5 years, iBio's Gains from Investment Securities peaked at $5.7 million during Q4 2021, and registered a low of $10000.0 during Q1 2022.
  • Moreover, its 5-year median value for Gains from Investment Securities was $73000.0 (2024), whereas its average is $465750.0.
  • Data for iBio's Gains from Investment Securities shows a peak YoY increase of 763243.24% (in 2021) and a maximum YoY decrease of 9689.28% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows iBio's Gains from Investment Securities stood at $5.7 million in 2021, then crashed by 85.77% to $814000.0 in 2022, then tumbled by 91.77% to $67000.0 in 2023, then rose by 10.45% to $74000.0 in 2024, then fell by 28.38% to $53000.0 in 2025.
  • Its Gains from Investment Securities stands at $53000.0 for Q3 2025, versus $78000.0 for Q2 2025 and $75000.0 for Q1 2025.